News Codexis, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
3.47 ^USD	+0.29%		+3.89%	+13.77%

May. 02	Earnings Flash (CDXS) CODEXIS Posts Q1 Revenue $17.1M, vs. Street Est of $13.3M	MT
May. 02	Transcript : Codexis, Inc., Q1 2024 Earnings Call, May 02, 2024

Codexis: Q1 Earnings Snapshot	May. 02	AQ
Codexis : Q1 2024 Results	May. 02	PU
Earnings Flash (CDXS) CODEXIS Posts Q1 Revenue $17.1M, vs. Street Est of $13.3M	May. 02	MT
Transcript : Codexis, Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Codexis Reports First Quarter 2024 Financial Results	May. 02	AQ
Codexis, Inc. Reiterates Financial Guidance for the Fiscal 2024	May. 02	CI
Codexis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Codexis to Report First Quarter 2024 Financial Results on May 2	Apr. 18	AQ
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board	Apr. 11	AQ
Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board	Apr. 11	CI
Benchmark Upgrades Codexis to Buy From Hold, Price Target is $9	Feb. 29	MT
Codexis: Q4 Earnings Snapshot	Feb. 28	AQ
Transcript : Codexis, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (CDXS) CODEXIS Reports Q4 Revenue $26.6M, vs. Street Est of $18.9M	Feb. 28	MT
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results	Feb. 28	AQ
Codexis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Codexis Shares Up 31% on Roche Licensing Agreement	Feb. 27	DJ
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche	Feb. 26	AQ
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche	Feb. 26	CI
Codexis to Participate in TD Cowen 44th Annual Health Care Conference	Feb. 26	AQ

No results for this search